RAP charting, page-4499

The thing that could hold back RAP is that it is at the moment just a indicator for respiratory illness's. Like people have said the shazzam of diagnosis through cough algorithms. If you take a look at this slide it seems they are setting it up just as a indicator.

Eg. telehealth appointment, the GP asks you to cough through Resapp program for the GP to receive a indication of what the problem COULD be. The patient will have to still physically go in for further checkup/tests and potential prescriptions.

If it passes FDA and all goes well for RAP it will be big but not as big as some might think it will be.

This is just my opinion. Not down ramping.